Skip to main content
Ben Goodger

Ben Goodger

Edwards Wildman Palmer UK LLP
Partner
Search Me on: Edwards Wildman

Results for: Ben Goodger

    • London Tel +44 (0) 20 7556 4188 | Fax +44 (0) 20 7716 3728

    Ben has over 20 years' experience in advising companies on the strategic management, commercialisation and protection of their valuable intellectual property. He has worked with clients in a number of industries, including bio-pharma, IT, food and drink, energy, and university technology transfer. He has advised many different types of client, including multinational corporations, SMEs, lenders, and academic institutions on issues relating to the commercialisation and licensing of IP. Ben spent two years in Shanghai, where he managed his previous firm’s China business and Asia commercial IP groups, and has internationally-recognised expertise in advising on strategies for the protection, commercialisation and management of IP assets in China and Asia.

    Ben is widely recognised as a leading IP practitioner. For the third consecutive year, Ben is listed by the Intellectual Asset Management (IAM) magazine in their 2014 editions of IAM Patent 1000 World's Leading Patent Practitioners and IAM Strategy 300 - The World’s Leading IP Strategists. He is also recognised in Chambers Global and UK Chambers legal directories. Ben is a founder member, and Fellow, of the International IP Strategists Association (INTIPSA). Ben is also included in the latest edition of ‘Best Lawyers' in the United Kingdom’ for Information Technology Law work.

    In 2014, Ben was named the exclusive winner in the Healthcare & Life Sciences category for the United Kingdom in the Lexology Client Choice Awards 2014 based on corporate counsel feedback.

    • Advised ASLAN Pharmaceuticals Pte Ltd, a pharmaceutical company headquartered in Singapore, on an innovative strategic partnership with Bristol-Myers Squibb, for the rapid development of BMS-777607, Bristol-Myers Squibb’s investigational small molecule inhibitor for treatment of solid tumours.

    • Handled the negotiations and drafting of a licence agreement from a NASDAQ-listed biopharma to develop an epidermal growth factor receptor (EGFR) inhibitor, entering Phase 2 development for solid tumours. Ben negotiated a deal to fund and globally develop the compound through proof of concept, initially targeting patients with gastric cancer, through a development program conducted in Asia; and then to identify a global partner for phase 3 development and commercialisation. Under the deal, the client will share a significant portion of the proceeds of such commercialisation.

    • Managed a four-year project involving the establishment of a strategic brand management company and reorganization of hundreds of internal licences for one of the world’s leading banks,
      involving complex transfer pricing issues.

    • Conducted a comprehensive review of a publicly listed energy technology company’s IP strategy, processes and procedures to advise on their adequacy, and where improvements could be made.

    • Advised a Canadian materials science company on a significant JV and investment in China, including dealing with a local challenge to title in the acquired IP.

    • Managed the world wide trade mark portfolio of one of the world’s leading drinks companies.

    • Advised an international software company on its IP protection position in China; and, subsequently advised on the roll out of this strategy globally.

    • Acted for a major UK broadcasting corporation on their acquisition of the copyright in a famous children’s publication, so it could be turned into an animated TV series.

    • Lead the IP due diligence on £$2 billion acquisition of the bulk chemical divisions of a major UK based chemical company for a global chemical company.

    • Advised one of the UK’s leading universities on how to regularize a historically complicated IP position upon its research being identified as of great commercial significance in treating a previously incurable condition.

    • Represented MARQUES (Association of European Brand Owners) at the United Nations in lobbying efforts on behalf of IP community in relation to UNCITRAL Legislative Guide on Secured Transactions.

    • Advised a leading UK research university on strategies for commercializing a ground-breaking platform technology.

    • Advised several companies on the divestment of patent portfolios to purchasers in China.

    Featured Experience

    • Disposal of Avangate Group to Francisco Partners

      Our cross-border team comprising lawyers from the Chicago, London, Boston, LA, New York and Providence offices, successfully represented the sellers (comprising Romanian serial tech entrepreneur Radu Georgescu, 3TS Capital Partners' CEE technology fund and the management team) in connection with the disposal of the Avangate Group to Francisco Partners. MORE

    • Disposal of Avangate Group to Francisco Partners

      Our cross-border team comprising lawyers from the Chicago, London, Boston, LA, New York and Providence offices, successfully represented the sellers (comprising Romanian serial tech entrepreneur Radu Georgescu, 3TS Capital Partners' CEE technology fund and the management team) in connection with the disposal of the Avangate Group to Francisco Partners. MORE

    • Disposal of Avangate Group to Francisco Partners

      Our cross-border team comprising lawyers from the Chicago, London, Boston, LA, New York and Providence offices, successfully represented the sellers (comprising Romanian serial tech entrepreneur Radu Georgescu, 3TS Capital Partners' CEE technology fund and the management team) in connection with the disposal of the Avangate Group to Francisco Partners. MORE

    • Disposal of Avangate Group to Francisco Partners

      Our cross-border team comprising lawyers from the Chicago, London, Boston, LA, New York and Providence offices, successfully represented the sellers (comprising Romanian serial tech entrepreneur Radu Georgescu, 3TS Capital Partners' CEE technology fund and the management team) in connection with the disposal of the Avangate Group to Francisco Partners. MORE

    • Disposal of Avangate Group to Francisco Partners

      Our cross-border team comprising lawyers from the Chicago, London, Boston, LA, New York and Providence offices, successfully represented the sellers (comprising Romanian serial tech entrepreneur Radu Georgescu, 3TS Capital Partners' CEE technology fund and the management team) in connection with the disposal of the Avangate Group to Francisco Partners. MORE

    • Disposal of Avangate Group to Francisco Partners

      Our cross-border team comprising lawyers from the Chicago, London, Boston, LA, New York and Providence offices, successfully represented the sellers (comprising Romanian serial tech entrepreneur Radu Georgescu, 3TS Capital Partners' CEE technology fund and the management team) in connection with the disposal of the Avangate Group to Francisco Partners. MORE

    • Disposal of Avangate Group to Francisco Partners

      Our cross-border team comprising lawyers from the Chicago, London, Boston, LA, New York and Providence offices, successfully represented the sellers (comprising Romanian serial tech entrepreneur Radu Georgescu, 3TS Capital Partners' CEE technology fund and the management team) in connection with the disposal of the Avangate Group to Francisco Partners. MORE

    • Data Protection Counsel for Manufacturer

      Edwards Wildman IP and Data Protection team advises a US-based manufacturer of goods used in the travel industry, managing a program to achieve compliance with differing data protection regimes across the EU. MORE

    • Data Protection Counsel for Manufacturer

      Edwards Wildman IP and Data Protection team advises a US-based manufacturer of goods used in the travel industry, managing a program to achieve compliance with differing data protection regimes across the EU. MORE

    • Data Protection Counsel for Manufacturer

      Edwards Wildman IP and Data Protection team advises a US-based manufacturer of goods used in the travel industry, managing a program to achieve compliance with differing data protection regimes across the EU. MORE

    • Data Protection Counsel for Manufacturer

      Edwards Wildman IP and Data Protection team advises a US-based manufacturer of goods used in the travel industry, managing a program to achieve compliance with differing data protection regimes across the EU. MORE

    • Data Protection Counsel for Manufacturer

      Edwards Wildman IP and Data Protection team advises a US-based manufacturer of goods used in the travel industry, managing a program to achieve compliance with differing data protection regimes across the EU. MORE

    • Data Protection Counsel for Manufacturer

      Edwards Wildman IP and Data Protection team advises a US-based manufacturer of goods used in the travel industry, managing a program to achieve compliance with differing data protection regimes across the EU. MORE

    • Data Protection Counsel for Manufacturer

      Edwards Wildman IP and Data Protection team advises a US-based manufacturer of goods used in the travel industry, managing a program to achieve compliance with differing data protection regimes across the EU. MORE

    • Data Protection Counsel for Manufacturer

      Edwards Wildman IP and Data Protection team advises a US-based manufacturer of goods used in the travel industry, managing a program to achieve compliance with differing data protection regimes across the EU. MORE

    • Data Protection Counsel for Manufacturer

      Edwards Wildman IP and Data Protection team advises a US-based manufacturer of goods used in the travel industry, managing a program to achieve compliance with differing data protection regimes across the EU. MORE

    • Data Protection Counsel for Manufacturer

      Edwards Wildman IP and Data Protection team advises a US-based manufacturer of goods used in the travel industry, managing a program to achieve compliance with differing data protection regimes across the EU. MORE

    • Data Protection Counsel for Manufacturer

      Edwards Wildman IP and Data Protection team advises a US-based manufacturer of goods used in the travel industry, managing a program to achieve compliance with differing data protection regimes across the EU. MORE

    • ASLAN License with Bristol Myers Squibb

      Our London Life Sciences team advised ASLAN Pharmaceuticals Pte Ltd, a pharmaceutical company headquartered in Singapore, on an innovative strategic partnership with Bristol-Myers Squibb, for the rapid development of BMS-777607, Bristol-Myers Squibb’s investigational small molecule inhibitor for treatment of solid tumors. MORE

    • ASLAN Pharmaceuticals license of Array BioPharma Cancer Drug

      Our London Life Sciences lawyers advised ASLAN Pharmaceuticals Pte Ltd in the licensing of a drug compound by ASLAN from Array. MORE

    • ASLAN License with Bristol Myers Squibb

      Our London Life Sciences team advised ASLAN Pharmaceuticals Pte Ltd, a pharmaceutical company headquartered in Singapore, on an innovative strategic partnership with Bristol-Myers Squibb, for the rapid development of BMS-777607, Bristol-Myers Squibb’s investigational small molecule inhibitor for treatment of solid tumors. MORE

    • ASLAN Pharmaceuticals license of Array BioPharma Cancer Drug

      Our London Life Sciences lawyers advised ASLAN Pharmaceuticals Pte Ltd in the licensing of a drug compound by ASLAN from Array. MORE

    • ASLAN License with Bristol Myers Squibb

      Our London Life Sciences team advised ASLAN Pharmaceuticals Pte Ltd, a pharmaceutical company headquartered in Singapore, on an innovative strategic partnership with Bristol-Myers Squibb, for the rapid development of BMS-777607, Bristol-Myers Squibb’s investigational small molecule inhibitor for treatment of solid tumors. MORE

    • ASLAN Pharmaceuticals license of Array BioPharma Cancer Drug

      Our London Life Sciences lawyers advised ASLAN Pharmaceuticals Pte Ltd in the licensing of a drug compound by ASLAN from Array. MORE

    • ASLAN License with Bristol Myers Squibb

      Our London Life Sciences team advised ASLAN Pharmaceuticals Pte Ltd, a pharmaceutical company headquartered in Singapore, on an innovative strategic partnership with Bristol-Myers Squibb, for the rapid development of BMS-777607, Bristol-Myers Squibb’s investigational small molecule inhibitor for treatment of solid tumors. MORE

    • ASLAN Pharmaceuticals license of Array BioPharma Cancer Drug

      Our London Life Sciences lawyers advised ASLAN Pharmaceuticals Pte Ltd in the licensing of a drug compound by ASLAN from Array. MORE

    Before Edwards Wildman

    Ben was for 13 years a partner and Head of IP Commercialisation at an international IP specialist firm. For two years of that time he lived and worked in Shanghai and managed the China business of his firm. Prior to that he was at firms in Oxford, and the City of London. He spent part of the early part of his career trying his hand at public international law in Paris.

    Ben is a past president of the Licensing Executives Society of Great Britain and Ireland and a member of both the IP Committee of the China Britain Business Council and the editorial advisory board of Global IP Asset Management Report. He is one of the founders of the International IP Strategists Association (INTIPSA). He also founded the Thames Valley Branch of the Society for Computers and Law.

    Besides Edwards Wildman

    Ben is married to Philippa and they have three children, none of whom show the slightest sign of being interested in pursuing a career in the law. His main passions when not at work are: architecture (this borders on obsession; at University he was President of the Architectural Society); playing his bassoon; writing a horror short story each Halloween; and drawing / painting.

    Education +-

    Courts+-

    Memberships+-

    Languages+-

    The hiring of a lawyer is an important decision that should not be based solely on advertisements. Prior results do not guarantee a similar outcome.